Acumen Pharmaceuticals
ABOS
50 hedge funds and large institutions have $278M invested in Acumen Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 12 closing their positions.
710% more call options, than puts
Call options by funds: $4.07M | Put options by funds: $503K
131% more capital invested
Capital invested by funds: $120M → $278M (+$158M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
6% more funds holding
Funds holding: 47 → 50 (+3)
5.27% more ownership
Funds ownership: 63.28% → 68.55% (+5.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$6.31M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$3.89M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$3.28M |
| 4 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$2.91M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$2.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$9.05M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.81M |
| 3 |
Millennium Management
New York
|
-$672K |
| 4 |
PA
Perceptive Advisors
New York
|
-$623K |
| 5 |
GPC
Guardian Point Capital
Charlottesville,
Virginia
|
-$574K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citadel Advisors
Miami,
Florida
| – | -$308K | -53,749 | Closed |
|
|
VF
52
Virtu Financial
New York
| – | -$123K | -26,204 | Closed |
|
53
Marshall Wace
London,
United Kingdom
| – | -$89K | -18,808 | Closed |
|
|
PCM
54
Prelude Capital Management
New York
| – | -$87K | -18,500 | Closed |
|
55
Two Sigma Investments
New York
| – | -$72K | -15,311 | Closed |
|
|
E
56
Ergoteles
New York
| – | -$52K | -11,113 | Closed |
|
57
Simplex Trading
Chicago,
Illinois
| – | -$15.3K | -2,672 | Closed |
|
58
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$5K | -1,000 | Closed |
|
|
PHK
59
Point72 Hong Kong
Hong Kong
| – | -$1K | -292 | Closed |
|
60
New York State Common Retirement Fund
Albany,
New York
| – | -$1K | -257 | Closed |
|
ABOS Hedge Fund Activity: Q3 2022 in Review
50 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q3 2022, worth a combined $278M — up 131% from $120M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ABOS positions and 12 closed out — a net gain of 3 holders — while 17 added to existing stakes and 11 trimmed.
The largest buyer was Commodore Capital, opening a new position worth an estimated $6.31M. The largest seller was BlackRock, cutting an estimated $9.05M.
- 50 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q3 2022, up from 47 in Q2 2022.
- Funds reported $278M of Acumen Pharmaceuticals stock for Q3 2022, up 131% quarter-over-quarter.
- 15 funds opened new Acumen Pharmaceuticals positions in Q3 2022 and 12 closed out, a net change of +3 holders.
- The largest Acumen Pharmaceuticals buyer in Q3 2022 was Commodore Capital, an estimated $6.31M added.
- The largest Acumen Pharmaceuticals seller in Q3 2022 was BlackRock, an estimated $9.05M sold.
Based on aggregated 13F filings for Q3 2022.